New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
New York Times
There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.
https://www.nytimes.com/2023/12/08/health/casgevy-lyfgenia-sickle-cell-africa.html